Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic Treg reduction and effector T cell activation

Tanja de Gruijl on LinkedIn: Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin…

Frontiers Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy

Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors

Steps involved with T-cell activation as well as its negative

Cytotoxic T lymphocyte-associated antigen-4 blockade restores T cell

Full article: Advances in the development of tumor-infiltrating lymphocyte therapy for advanced melanoma

Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies

Role of Naturally Arising Regulatory T Cells in Hematopoietic Cell Transplantation - Biology of Blood and Marrow Transplantation

Smart drug delivery systems to overcome drug resistance in cancer immunotherapy

B7-H3 in Brain Malignancies: Immunology and Immunotherapy

Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic Treg reduction and effector T cell activation

Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy, EJNMMI Research

Overcoming the limitations of immunotherapy in pancreatic ductal adenocarcinoma: Combining radiotherapy and metabolic targeting therapy

CTLA-4: Checkpoints beyond the membrane: Molecular Therapy